A 12-Week, Double-Blind, Placebo-Controlled, Phase 2a Study to Investigate the Safety, Tolerability and Efficacy of MBS2320 in Patients With Active Rheumatoid Arthritis Receiving Methotrexate
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 24 Nov 2018
At a glance
- Drugs MBS 2320 (Primary) ; Methotrexate
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- Sponsors Modern Biosciences
- 15 Nov 2018 Planned primary completion date changed from 1 Aug 2018 to 1 Nov 2018.
- 15 Nov 2018 Status changed from recruiting to active, no longer recruiting.
- 29 Aug 2017 Status changed from not yet recruiting to recruiting.